CLINICAL TRIALS PROFILE FOR POLIVY

All Clinical Trials for POLIVY

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04231877 ↗	Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma	Recruiting	Genentech, Inc.	Phase 1	2020-10-27	This phase I trial studies the side effects of polatuzumab vedotin when given with combination chemotherapy for the treatment of patients with untreated large B-cell lymphoma that grows and spreads quickly and has severe symptoms (aggressive). Polatuzumab vedotin is a monoclonal antibody, polatuzumab, linked to a toxic agent called vedotin. Polatuzumab attaches to CD79B positive cancer cells in a targeted way and delivers vedotin to kill them. Drugs used in combination chemotherapy such as etoposide, cyclophosphamide, and doxorubicin work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as prednisone, lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Giving polatuzumab vedotin in addition to etoposide, prednisone, cyclophosphamide, doxorubicin and rituximab may help treat patients with aggressive large B-cell lymphoma.
NCT04231877 ↗	Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma	Recruiting	National Cancer Institute (NCI)	Phase 1	2020-10-27	This phase I trial studies the side effects of polatuzumab vedotin when given with combination chemotherapy for the treatment of patients with untreated large B-cell lymphoma that grows and spreads quickly and has severe symptoms (aggressive). Polatuzumab vedotin is a monoclonal antibody, polatuzumab, linked to a toxic agent called vedotin. Polatuzumab attaches to CD79B positive cancer cells in a targeted way and delivers vedotin to kill them. Drugs used in combination chemotherapy such as etoposide, cyclophosphamide, and doxorubicin work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as prednisone, lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Giving polatuzumab vedotin in addition to etoposide, prednisone, cyclophosphamide, doxorubicin and rituximab may help treat patients with aggressive large B-cell lymphoma.
NCT04231877 ↗	Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma	Recruiting	University of Washington	Phase 1	2020-10-27	This phase I trial studies the side effects of polatuzumab vedotin when given with combination chemotherapy for the treatment of patients with untreated large B-cell lymphoma that grows and spreads quickly and has severe symptoms (aggressive). Polatuzumab vedotin is a monoclonal antibody, polatuzumab, linked to a toxic agent called vedotin. Polatuzumab attaches to CD79B positive cancer cells in a targeted way and delivers vedotin to kill them. Drugs used in combination chemotherapy such as etoposide, cyclophosphamide, and doxorubicin work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as prednisone, lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Giving polatuzumab vedotin in addition to etoposide, prednisone, cyclophosphamide, doxorubicin and rituximab may help treat patients with aggressive large B-cell lymphoma.
NCT04659044 ↗	Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	Not yet recruiting	National Cancer Institute (NCI)	Phase 2	2021-12-31	This phase II trial studies the effect of polatuzumab vedotin, venetoclax, and rituximab and hyaluronidase human in treating patients with mantle cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Polatuzumab vedotin is a monoclonal antibody, polatuzumab, linked to a toxic agent called vedotin. Polatuzumab attaches to CD79B positive cancer cells in a targeted way and delivers vedotin to kill them. Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cell growth. Rituximab hyaluronidase is a combination of rituximab and hyaluronidase. Rituximab binds to a molecule called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Hyaluronidase allows rituximab to be given by injection under the skin. Giving rituximab and hyaluronidase by injection under the skin is faster than giving rituximab alone by infusion into the blood. Giving polatuzumab vedotin, venetoclax, and rituximab and hyaluronidase human may work better than standard therapy in treating patients with mantle cell lymphoma.
NCT04659044 ↗	Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	Not yet recruiting	Academic and Community Cancer Research United	Phase 2	2021-12-31	This phase II trial studies the effect of polatuzumab vedotin, venetoclax, and rituximab and hyaluronidase human in treating patients with mantle cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Polatuzumab vedotin is a monoclonal antibody, polatuzumab, linked to a toxic agent called vedotin. Polatuzumab attaches to CD79B positive cancer cells in a targeted way and delivers vedotin to kill them. Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cell growth. Rituximab hyaluronidase is a combination of rituximab and hyaluronidase. Rituximab binds to a molecule called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Hyaluronidase allows rituximab to be given by injection under the skin. Giving rituximab and hyaluronidase by injection under the skin is faster than giving rituximab alone by infusion into the blood. Giving polatuzumab vedotin, venetoclax, and rituximab and hyaluronidase human may work better than standard therapy in treating patients with mantle cell lymphoma.
NCT04665765 ↗	Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Recruiting	National Cancer Institute (NCI)	Phase 2	2021-01-18	This phase II trial studies the effect of polatuzumab vedotin, rituximab, ifosfamide, carboplatin, and etoposide as initial salvage therapy in treating patients with diffuse large B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Polatuzumab vedotin is a monoclonal antibody, polatuzumab, linked to a toxic agent called vedotin. Polatuzumab attaches to CD79b positive cancer cells in a targeted way and delivers vedotin to kill them. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Chemotherapy drugs, such as ifosfamide, carboplatin, and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy with immunotherapy may kill more cancer cells in patients with diffuse large B-cell lymphoma.
NCT04665765 ↗	Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Recruiting	City of Hope Medical Center	Phase 2	2021-01-18	This phase II trial studies the effect of polatuzumab vedotin, rituximab, ifosfamide, carboplatin, and etoposide as initial salvage therapy in treating patients with diffuse large B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Polatuzumab vedotin is a monoclonal antibody, polatuzumab, linked to a toxic agent called vedotin. Polatuzumab attaches to CD79b positive cancer cells in a targeted way and delivers vedotin to kill them. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Chemotherapy drugs, such as ifosfamide, carboplatin, and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy with immunotherapy may kill more cancer cells in patients with diffuse large B-cell lymphoma.

Clinical Trial Conditions for POLIVY

Condition Name

Condition Name for POLIVY
Intervention	Trials
Aggressive Non-Hodgkin Lymphoma	2
Primary Mediastinal (Thymic) Large B-Cell Lymphoma	2
Recurrent Diffuse Large B-Cell Lymphoma	2
Refractory Diffuse Large B-Cell Lymphoma	2

Condition MeSH

Condition MeSH for POLIVY
Intervention	Trials
Lymphoma	10
Lymphoma, B-Cell	7
Lymphoma, Non-Hodgkin	5
Lymphoma, Large B-Cell, Diffuse	4

Clinical Trial Locations for POLIVY

Trials by Country

Trials by Country for POLIVY
Location	Trials
United States	18
Czechia	1

Trials by US State

Trials by US State for POLIVY
Location	Trials
Washington	3
California	2
New York	2
Missouri	2
Oklahoma	1

Clinical Trial Progress for POLIVY

Clinical Trial Phase

Clinical Trial Phase for POLIVY
Clinical Trial Phase	Trials
Phase 2	9
Phase 1/Phase 2	1
Phase 1	2

Clinical Trial Status

Clinical Trial Status for POLIVY
Clinical Trial Phase	Trials
Not yet recruiting	8
Recruiting	4

Clinical Trial Sponsors for POLIVY

Sponsor Name

Sponsor Name for POLIVY
Sponsor	Trials
National Cancer Institute (NCI)	5
Genentech, Inc.	4
University of Washington	2

Sponsor Type

Sponsor Type for POLIVY
Sponsor	Trials
Other	11
NIH	5
Industry	5

POLIVY clinical trials update, market analysis, and exclusivity timeline (polatuzumab vedotin-piiq)

Last updated: July 26, 2026

Polivy (polatuzumab vedotin-piiq) has two FDA-approved label settings built around combination chemotherapy in previously untreated and relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBCL). The near-term market outlook is dominated by (1) durability of first-line uptake, (2) post-2019 R/R penetration dynamics, and (3) competitive pressure from other next-generation antibody-drug conjugates (ADCs) and cellular therapies in DLBCL. Patent and regulatory entry risks for biosimilars do not apply in the same way as for small molecules, but the ability of competitors to attack indications, formulations, and manufacturing/process IP still shapes launch and switching risk.

---

What is Polivy (polatuzumab vedotin) approved for, and what does its FDA label cover?

Bottom line: Polivy is approved as an antibody-drug conjugate combination therapy. The key commercial levers are the labeled regimens and line-of-therapy positioning in DLBCL/HGBCL.

Key FDA-approved clinical settings

Polivy is marketed by Genentech (member of Roche Group) in the US. Its label is centered on DLBCL-related combinations rather than monotherapy.

Core label structures (US):

• Previously untreated DLBCL or HGBCL: Polivy combined with R-CHP (rituximab plus cyclophosphamide, doxorubicin, prednisone) regimen.
• Relapsed/refractory (R/R) DLBCL after at least two prior therapies: Polivy combined with bendamustine and rituximab (BR).
• Other R/R DLBCL/HGBCL label elements are constrained by prior-therapy lines and required companion regimens (commercially important because it narrows eligible prescribers).

Mechanism and why it matters for uptake

Polivy links an anti-CD79b antibody to the cytotoxic payload monomethyl auristatin E (MMAE) via a cleavable linker. In practice, uptake depends on:

• regimen fit with local standard-of-care,
• predictable toxicity management relative to chemoimmunotherapy,
• and clinician familiarity with ADC logistics.

---

Which clinical trials drive the next Polivy expansion, and what is the latest direction?

Bottom line: Polivy’s pipeline strategy is typically “label expansion and consolidation,” meaning trials target earlier lines, modified backbones, and patient subsets where CD79b targeting has clinical signal.

What trial categories typically move Polivy’s commercial trajectory

1. Front-line intensification or substitution (swap or add Polivy into standard first-line DLBCL pathways).
2. R/R sequencing trials (Polivy before or after CAR-T, bispecific antibodies, or other ADCs).
3. Biomarker-stratified cohorts to support payer and guideline uptake.

Clinical development pattern that affects market timing

• If a trial supports a broader label earlier in line of therapy, the market impact is immediate because it moves patient volumes into the Polivy addressable population.
• If trials only refine post–standard therapies, incremental uptake depends on real-world sequencing behavior, which is slower to change.

Trial update format for investors and litigators

A market-relevant “update” should be read through three lenses:

• primary endpoint success (ORR/CR vs PFS vs OS),
• strength of comparator (historical vs randomized),
• and regimen feasibility (dose intensity, discontinuation, hospital resource utilization).

No trial-by-trial “latest results” can be stated here without a specific dataset or publication listing.

---

How big is Polivy’s addressable market in DLBCL, and what are the key drivers of growth vs stagnation?

Bottom line: The growth ceiling is line-of-therapy expansion and guideline adoption. Stagnation comes from sequencing displacement by cellular therapy and bispecifics, plus competing ADCs in R/R DLBCL.

Addressable patient volume framework

Commercial TAM for Polivy is determined by:

• incidence of DLBCL/HGBCL,
• eligible prior-therapy lines per label,
• performance status constraints,
• and availability of combination backbone drugs.

Key uptake drivers

• Earlier adoption in first-line if clinical guidelines prefer chemoimmunotherapy plus CD79b targeting.
• Repeat use in subsequent cycles depends on tolerability and ability to complete regimen with planned dosing.
• Reimbursement and prior authorization smoothness for ADC regimens.

Key headwinds

• Competitive ADC class pressure: other CD79b-directed or alternate payload ADCs seek similar niches.
• CAR-T and bispecific displacement: R/R DLBCL sequencing increasingly uses cellular therapies and T-cell redirectors; Polivy’s role can narrow to bridging or second salvage rather than a later-line destination.

---

What is the revenue projection for Polivy, and how do base-case scenarios change with uptake?

Bottom line: Forecasting Polivy requires an explicit baseline (current quarterly US revenue, international split, and uptake by line-of-therapy). That input is not provided, so no complete, auditable projection can be produced.

No market numbers can be stated without a defined starting revenue run-rate and a cited market model.

---

When does Polivy lose exclusivity, and what is the patent estate’s real impact on generic risk?

Bottom line: Polivy’s exclusivity and generic risk are governed by (1) reference product biologics-style exclusivity for a complex drug, and (2) the layered patent estate typical for ADCs: composition, linker/payload, conjugation processes, and formulation.

Exclusivity timeline mechanics for ADCs

• For complex biologic-like products, “exclusivity” is often a combination of:
  • FDA exclusivity protections tied to first approval and certain supplemental applications, and
  • patent exclusivity tied to claims that cover the drug substance and/or manufacturing and formulation.

What determines generic entry feasibility

Even if a regulatory pathway exists, commercial generic entry is typically blocked by:

• process patents for conjugation and purification,
• payload linkage and stability claims,
• and formulation/process claims controlling drug release and shelf life.

No specific expiration dates or patent numbers can be supplied without a sourced Orange Book / FDA patent list and assignment chain.

---

What patents protect Polivy, and where are the likely barriers to biosimilar or generic entry?

Bottom line: ADC IP typically concentrates in:

• antibody sequences/epitopes (or protected antibody constructs),
• conjugation/linker chemistry,
• payload or payload-linker composition,
• manufacturing steps and release specs,
• and formulation conditions affecting stability.

IP asset categories that matter in litigation

• Method-of-manufacture claims: purification and conjugation steps are often the main litigation battlefield.
• Drug substance composition claims: define conjugate distribution, DAR (drug-antibody ratio) bands, and stability.
• Formulation claims: include buffer systems, lyophilized vs liquid presentation, and excipient profiles.

A complete patent landscape requires sourced listing data.

---

What is the Orange Book status of Polivy, and which companies are positioned for Paragraph IV challenges?

Bottom line: Orange Book status is the starting point for generic or follow-on entry risk. Paragraph IV challenges are tied to ANDA referencing and are not applicable the same way for biologics.

No Orange Book listings, patent numbers, or Paragraph IV filers can be stated here without the referenced FDA patent list.

---

What Polivy formulation and manufacturing patents affect supply risk during competition?

Bottom line: For ADCs, manufacturing IP impacts whether a competitor can scale while meeting stability and quality constraints that preserve clinical performance.

Manufacturing risk points

• conjugation reaction control,
• impurity removal (free payload and aggregate levels),
• DAR distribution control,
• stability in the commercial presentation.

A sourcing-backed manufacturing IP inventory is required for a credible barrier assessment.

---

How does Polivy compare with other DLBCL therapies on market trajectory and sequencing position?

Bottom line: Polivy competes in a crowded DLBCL R/R landscape where sequencing decisions can re-route patients before they reach Polivy.

Competitive pressure map (high level)

• CAR-T: often used after multiple lines and when eligible. It can reduce Polivy later-line volume.
• Bispecific antibodies: accelerate early R/R penetration in some lines, narrowing Polivy’s role.
• Competing ADCs: can capture patients that Polivy targets if their safety or efficacy balance differs.
• Chemoimmunotherapy backbone: if the backbone changes standard-of-care, Polivy’s combinations can see adoption friction.

No market-share table can be produced without cited sales data.

---

What generic launch scenarios are realistic for Polivy, and what would trigger share loss?

Bottom line: A realistic trigger is the combination of regulatory readiness (ANDA pathway if applicable), viable IP design-around, and successful payer switching.

Share-loss triggers

• label changes or new guideline de-emphasis,
• meaningful reductions in clinician adoption due to safety management issues,
• competitor wins on efficacy endpoints that drive guideline updates,
• and economic contracting that favors alternatives.

No scenario timing can be stated without exclusivity dates and patent expiration mapping.

---

Key Takeaways

• Polivy’s commercial resilience depends on maintaining its labeled position in DLBCL/HGBCL combination regimens across line-of-therapy, not on monotherapy expansion.
• The main growth lever is label expansion into earlier lines or broader eligible subgroups, which shifts patient volumes.
• The main risk is sequencing displacement in R/R by CAR-T and bispecific therapies, plus competitive ADC class pressure.
• A credible exclusivity and patent-barrier view requires Orange Book patent list data and a sourced patent estate inventory; those inputs are not present here, so no actionable dates can be provided.

---

FAQs

1. Which clinical endpoints are most important to predict Polivy label expansion?
2. How does Polivy’s tolerability profile influence real-world uptake versus other ADCs?
3. What DLBCL sequencing patterns most reduce Polivy exposure in relapsed/refractory disease?
4. What regulatory exclusivities typically block follow-on versions of ADCs like Polivy?
5. What manufacturing quality attributes drive switching decisions if a competitor enters the market?

---

References (APA)

1. None (no source documents were provided or cited in the response).